BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 13.52B |
| Revenue (ttm) | 502.08M |
| Net Income (ttm) | -724.93M |
| Shares Out | 193.86M |
| EPS (ttm) | -3.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,627,743 |
| Open | 82.97 |
| Previous Close | 74.52 |
| Day's Range | 69.30 - 84.68 |
| 52-Week Range | 31.77 - 84.94 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 86.04 (+23.39%) |
| Earnings Date | Apr 29, 2026 |
About BBIO
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price target is $86.04, which is an increase of 23.39% from the latest price.
News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic cond...
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418's rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically ...
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic cond...
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress
Limb-girdle muscular dystrophy type R9 (LGMDR9, formerly 2I) is a rare genetic disease caused by mutations in the FKRP gene.
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified s...
BridgeBio Pharma Transcript: Barclays 28th Annual Global Healthcare Conference
Patent litigation over Vyndamax is progressing with strong scientific backing, while Vyndaqel generics are not expected to disrupt the market. Multiple late-stage programs, including ADH1 and LGMD2I, show strong clinical data and significant commercial potential, with a decentralized launch strategy and robust pipeline expansion planned.
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
William Blair initiated coverage on the commercial-stage biotech, highlighting the company's expanding pipeline of treatments targeting rare genetic conditions.
BridgeBio Pharma Transcript: Leerink Global Healthcare Conference 2026
TTR therapy growth is accelerating, with strong clinical data and stable pricing, while European launches are expanding. The pipeline includes differentiated oral therapies for achondroplasia and hypochondroplasia, with global launches planned. Margin profile remains strong due to low COGS and minimal royalties.
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic cond...
BridgeBio Pharma Transcript: TD Cowen 46th Annual Health Care Conference
Stock volatility is linked to TAF IP uncertainty, but fundamentals remain strong with three positive Phase 3 readouts and multiple product launches planned. ATTR franchise shows sustained growth, and new launches are expected to be efficient and well-supported by existing infrastructure.
BridgeBio Pharma Earnings Call Transcript: Q4 2025
Strong Q4 and full-year revenue growth driven by Attruby's commercial momentum and positive late-stage pipeline results. Cash burn is stabilizing, with expectations for cash generation by 2028 and robust capital to support upcoming global launches.
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio to Participate in March Investor Conferences
PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio Pharma Transcript: Study result
The PROPEL-3 phase III trial of oral infigratinib in children with achondroplasia met all primary and key secondary endpoints, showing unprecedented gains in height velocity, Z-score, and body proportionality, with a strong safety profile. The therapy is positioned as a first-in-class oral option, with regulatory filings planned for 2026 and significant commercial potential.
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the fir...
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic diseases, an...
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively
BridgeBio Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals outlined its strategy to become a fully integrated biopharma, highlighting late-stage progress for azetukalner in epilepsy and neuropsychiatry, with top-line phase III data expected soon. Strong efficacy, rapid onset, and a favorable safety profile support commercial optimism, while early-stage pipeline advances in pain and CNS disorders offer future growth opportunities.
BridgeBio Pharma Transcript: Investor Update
Infigratinib, an oral FGFR1-3 inhibitor, shows robust efficacy and safety in achondroplasia, with Phase 2 data demonstrating significant improvements in growth and proportionality. Market research reveals strong physician and family preference for an oral option, with top-line Phase 3 results expected soon.
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...